Best of ADA China 2026 TOP TALK第三期丨T2DM治疗进入“代谢重塑+早期强化”新时代

参考文献

[1]中华医学会糖尿病学分会. 中国糖尿病防治指南（2024版）[J]. 中华糖尿病杂志,2025,17(1):16-139.

[2]中国研究型医院学会糖尿病学专业委员会. 成人2型糖尿病患者口服降糖药物三联优化方案（二甲双胍+二肽基肽酶Ⅳ抑制剂+钠-葡萄糖共转运蛋白2抑制剂）中国专家共识（2025年更新版）[J]. 中华糖尿病杂志,2025,17(8):934-949.

[3]19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026); Barcelona, Cataluña, Spain; March 11-14, 2026

[4]1667-P Patient-Reported Outcomes in Adults Initiating Treatment with Tirzepatide or Intensified Conventional Care Early in the Course of T2D: Results after Two Years of Treatment in SURPASS-EARLY.ADA 2026

[5]Nicholls SJ, et al. EASD 2025

[6]2026 ADA. The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy

[7]杨雁,陈颖,张惠杰,等. 糖尿病患者体重管理专家共识（2024版）[J]. 中华糖尿病杂志,2024,16(9):959-971.

[8]Orforglipron vs. Dapagliflozin in Type 2 Diabetes Inadequately Controlled with Metformin.ADA 2026.1254-OR

[9]Francesco Giorgino,et al.Efficacy and safety of Orforglipron vs Placebo Added to Titrated Insulin Glargine in Adults with Long-Standing Type 2 Diabetes: ACHIEVE-5.ADA 2026.1253-OR

[10]https://investor.lilly.com/node/53961

[11]https://investor.lilly.com/news-releases/news-release-details/achieve-4-longest-phase-3-study-lillys-foundayo-orforglipron?f_link_type=f_linkinlinenote&flow_extra=eyJpbmxpbmVfZGlzcGxheV9wb3NpdGlvbiI6MCwiZG9jX3Bvc2l0aW9uIjowLCJkb2NfaWQiOiI1MmUyZDUzYmQwNDZkNDE2LTRkYzJkYmJhODU1MTE4N2UifQ%3D%3D